CoChat
Sign Up
Cited by 392Gut microbiota and healthFatty Acid Research and HealthAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids

Open access
Miyamoto, Junki, Igarashi, Miki, Watanabe, Keita, Karaki, Shin-ichiro, Mukouyama, Hiromi, Kishino, Shigenobu, Li, Xuan, Ichimura, Atsuhiko, Irie, Junichiro, Sugimoto, Yukihiko, Mizutani, Tetsuya, Sugawara, Tatsuya, Miki, Takashi, Ogawa, Jun, Drucker, Daniel J., Arita, Makoto, Itoh, Hiroshi, Kimura, Ikuo·2019·Nature Communications
DOI 10.1038/s41467-019-11978-0PMC PMC6728375
Open this paper in CoChat — free accountOpen PDF

Abstract

Gut microbiota mediates the effects of diet, thereby modifying host metabolism and the incidence of metabolic disorders. Increased consumption of omega-6 polyunsaturated fatty acid (PUFA) that is abundant in Western diet contributes to obesity and related diseases. Although gut-microbiota-related metabolic pathways of dietary PUFAs were recently elucidated, the effects on host physiological function remain unclear. Here, we demonstrate that gut microbiota confers host resistance to high-fat diet (HFD)-induced obesity by modulating dietary PUFAs metabolism. Supplementation of 10-hydroxy- cis -12-octadecenoic acid (HYA), an initial linoleic acid-related gut-microbial metabolite, attenuates HFD-induced obesity in mice without eliciting arachidonic acid-mediated adipose inflammation and by improving metabolic condition via free fatty acid receptors. Moreover, Lactobacillus -colonized mice show similar effects with elevated HYA levels. Our findings illustrate the interplay between gut microbiota and host energy metabolism via the metabolites of dietary omega-6-FAs thereby shedding light on the prevention and treatment of metabolic disorders by targeting gut microbial metabolites.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-11978-0

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effects of dietary PUFAs on gut microbiota composition and PUFA metabolites. a Heat map of gut microbial PUFA metabolites in cecal content (n = 8 per group). b LA-derived gut microbial PUFA metabolites in cecal content were quantified (n = 7, 10, 8, 8, and 8 per group for HYA; n = 8,10, 8, 8, and 8 per group for HYB; n = 7, 10, 8, 8, and 10 per group for HYC; n = 8, 10, 8, 8, and 10 per group for KetoA; n = 7, 10, 7, 8, and 8 per group for KetoB; n = 8, 9, 8, 8, and 8 per group for KetoC). *P < 0.05 (Tukey–Kramer test). c–e Gut microbial composition was evaluated in order to determine the relative abundance of microbial taxa (c), diversity (d), and abundance of the bacterial domain at the family level (e) (n = 8, 10, and 7 per group). (−)_NC represents normal chow-fed mice, and (−)_HFD represents high-fat diet-fed mice. q < 0.05. Results are presented as means ± SE. Source data are provided as a Source Data file 1
Fig. 1 Effects of dietary PUFAs on gut microbiota composition and PUFA metabolites. a Heat map of gut microbial PUFA metabolites in cecal content (n = 8 per group). b LA-derived gut microbial PUFA metabolites in cecal content were quantified (n = 7, 10, 8, 8, and 8 per group for HYA; n = 8,10, 8, 8, and 8 per group for HYB; n = 7, 10, 8, 8, and 10 per group for HYC; n = 8, 10, 8, 8, and 10 per group for KetoA; n = 7, 10, 7, 8, and 8 per group for KetoB; n = 8, 9, 8, 8, and 8 per group for KetoC). *P < 0.05 (Tukey–Kramer test). c–e Gut microbial composition was evaluated in order to determine the relative abundance of microbial taxa (c), diversity (d), and abundance of the bacterial domain at the family level (e) (n = 8, 10, and 7 per group). (−)_NC represents normal chow-fed mice, and (−)_HFD represents high-fat diet-fed mice. q < 0.05. Results are presented as means ± SE. Source data are provided as a Source Data file 1CC BY · PubMed Central
Fig. 2 HYA-producing lactic acid bacteria. a The abundance of Lactobacillus was analyzed by qPCR (n = 9, 8, and 9 per group). b The abundance of the Lactobacillus strains (n = 7, 8, and 7 per group) and c the relative mRNA expression of metabolite-synthesizing enzymes (Cla-hy, Cla-dh, and Cla-er; see Supplementary Fig. 1) (n = 7 per group for Cla-hy; n = 8 per group for Cla-dh and Cla-er) in cecum were analyzed by qPCR and qRT-PCR. **P < 0.01, *P < 0.05 vs. NC (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. (−) (Tukey–Kramer test). (−)_HFD represents high-fat diet-fed mice. Results are presented as means ± SE. Source data are provided as a Source Data file 2
Fig. 2 HYA-producing lactic acid bacteria. a The abundance of Lactobacillus was analyzed by qPCR (n = 9, 8, and 9 per group). b The abundance of the Lactobacillus strains (n = 7, 8, and 7 per group) and c the relative mRNA expression of metabolite-synthesizing enzymes (Cla-hy, Cla-dh, and Cla-er; see Supplementary Fig. 1) (n = 7 per group for Cla-hy; n = 8 per group for Cla-dh and Cla-er) in cecum were analyzed by qPCR and qRT-PCR. **P < 0.01, *P < 0.05 vs. NC (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. (−) (Tukey–Kramer test). (−)_HFD represents high-fat diet-fed mice. Results are presented as means ± SE. Source data are provided as a Source Data file 2CC BY · PubMed Central
Fig. 3 Gut microbial PUFA metabolites improve host metabolic conditions. Changes in a body weight and b representative macroscopic appearance and tissue weights (n = 14 per group). Scale bar; 1 cm. epi, epididymal; peri, perirenal; sub, subcutaneous. c Hematoxylin–eosin (H&E)–stained WAT and the mean area of adipocytes (n = 8 per group). Scale bar, 400 μm. d Daily food intake measured at 7 weeks of age (n = 5 per group). e ITT (n = 10 per group) and f GTT (n = 10 per group) were analyzed at 13–14 weeks of age. g Blood glucose (n = 14 per group), h total plasma cholesterol (n = 10, 9, and 10 per group), i triglyceride (n = 10 per group), j PYY (n = 10, 9, and 8 per group), k GLP-1 (n = 8, 9, and 9 per group), and l insulin (n = 7, 8, and 8 per group) levels were measured at the end of the experimental period. m Fecal triglyceride levels were measured at 16 weeks of age (n = 10 per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. Source data are provided as a Source Data file 3
Fig. 3 Gut microbial PUFA metabolites improve host metabolic conditions. Changes in a body weight and b representative macroscopic appearance and tissue weights (n = 14 per group). Scale bar; 1 cm. epi, epididymal; peri, perirenal; sub, subcutaneous. c Hematoxylin–eosin (H&E)–stained WAT and the mean area of adipocytes (n = 8 per group). Scale bar, 400 μm. d Daily food intake measured at 7 weeks of age (n = 5 per group). e ITT (n = 10 per group) and f GTT (n = 10 per group) were analyzed at 13–14 weeks of age. g Blood glucose (n = 14 per group), h total plasma cholesterol (n = 10, 9, and 10 per group), i triglyceride (n = 10 per group), j PYY (n = 10, 9, and 8 per group), k GLP-1 (n = 8, 9, and 9 per group), and l insulin (n = 7, 8, and 8 per group) levels were measured at the end of the experimental period. m Fecal triglyceride levels were measured at 16 weeks of age (n = 10 per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. Source data are provided as a Source Data file 3CC BY · PubMed Central
Fig. 4 Gut microbial PUFA metabolites and adipose inflammatory response. a Heat map of FA profiles in the ileum (n = 4 per group). b HYA was detected in the ileum (left) and plasma (right) (n = 9 per group in the ileum; n = 9, 8, and 9 per group in the plasma). c Arachidonic acid (left) and PGE2 (right) were quantified in the ileum (n = 9 per group for arachidonic acid; n = 8, 9, and 9 per group for PGE2). d WAT sections were labeled by F4/80 (green), caveolin-1 (red), and DAPI (blue), and F4/80-positive cells were measured (n = 7 per group). Scale bar, 400 μm. e Levels of adipose PGE2 (n = 10 per group). f mRNA expression of F4/80, Tnfα, and Mcp1 in the WAT of HFD-induced obese mice (n = 10 per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. Source data are provided as a Source Data file 4
Fig. 4 Gut microbial PUFA metabolites and adipose inflammatory response. a Heat map of FA profiles in the ileum (n = 4 per group). b HYA was detected in the ileum (left) and plasma (right) (n = 9 per group in the ileum; n = 9, 8, and 9 per group in the plasma). c Arachidonic acid (left) and PGE2 (right) were quantified in the ileum (n = 9 per group for arachidonic acid; n = 8, 9, and 9 per group for PGE2). d WAT sections were labeled by F4/80 (green), caveolin-1 (red), and DAPI (blue), and F4/80-positive cells were measured (n = 7 per group). Scale bar, 400 μm. e Levels of adipose PGE2 (n = 10 per group). f mRNA expression of F4/80, Tnfα, and Mcp1 in the WAT of HFD-induced obese mice (n = 10 per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. Source data are provided as a Source Data file 4CC BY · PubMed Central
Fig. 5 HYA directly regulates glucose homeostasis and GLP-1 release. Individual FAs (HYA and LA; 1 g/kg) were administered by gavage, followed by a HYA quantification in plasma (left), ileum (center), and colon (right) (n = 8 animals). b Time-course changes in plasma GLP-1 from the tail vein was measured after oral administration of FAs (n = 7 animals per group). Basal GLP-1 concentration at time 0 was set as 100%. c OGTT was analyzed 2 h after individual FA administration (HYA and LA; 1 g/kg) by gavage (n = 8 animals per group). d Individual FAs were administered, and 2 h later, time-course changes in plasma insulin from the tail vein were measured after oral administration of glucose (n = 8 animals per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. e STC-1 cells were treated with LA-derived gut microbial metabolites [in a dose-dependent manner (20, 100, and 200 μM)], and GLP-1 concentration was measured in culture medium (n = 6 independent cultures from three biological replicates). **P < 0.01; *P < 0.05 vs. None (Tukey–Kramer test). f LA-derived gut microbial metabolites were detected in plasma of NC-fed mice (n = 8 animals). Results are presented as means ± SE. Source data are provided as a Source Data file 5
Fig. 5 HYA directly regulates glucose homeostasis and GLP-1 release. Individual FAs (HYA and LA; 1 g/kg) were administered by gavage, followed by a HYA quantification in plasma (left), ileum (center), and colon (right) (n = 8 animals). b Time-course changes in plasma GLP-1 from the tail vein was measured after oral administration of FAs (n = 7 animals per group). Basal GLP-1 concentration at time 0 was set as 100%. c OGTT was analyzed 2 h after individual FA administration (HYA and LA; 1 g/kg) by gavage (n = 8 animals per group). d Individual FAs were administered, and 2 h later, time-course changes in plasma insulin from the tail vein were measured after oral administration of glucose (n = 8 animals per group). **P < 0.01; *P < 0.05 vs. control (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA (Tukey–Kramer test). Results are presented as means ± SE. e STC-1 cells were treated with LA-derived gut microbial metabolites [in a dose-dependent manner (20, 100, and 200 μM)], and GLP-1 concentration was measured in culture medium (n = 6 independent cultures from three biological replicates). **P < 0.01; *P < 0.05 vs. None (Tukey–Kramer test). f LA-derived gut microbial metabolites were detected in plasma of NC-fed mice (n = 8 animals). Results are presented as means ± SE. Source data are provided as a Source Data file 5CC BY · PubMed Central
Fig. 6 HYA contributes to host metabolic condition via GPR40 and GPR120. Mobilization of [Ca2+]i induced by LA-derived gut microbial metabolites was monitored in Flp in a hGPR40 or b hGPR120 T-REx HEK293 cells. Data are presented as Ca2+ intensity. Cells were cultured for 24 h and then treated with or without 10 μg/mL doxycycline (n = 8 independent cultures with doxycycline from three biological replicates; n = 6 independent cultures without doxycycline from two biological replicates). Closed symbols represent values from cells treated with doxycycline, and open symbols denote untreated groups. c–f The inhibitory effects of c Gpr40 and Gpr120 siRNA, d MEK inhibitor (U0126), e PLC inhibitor (U73122), and f CaMKII inhibitor (KN-62) on GLP-1 secretion following LA, HYA, or HYB treatment (n = 4 independent cultures from two biological replicates). **P < 0.01 vs. None (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. LA (Tukey–Kramer test). $$P < 0.01 vs. HYA (Tukey–Kramer test). (−) represents untreated cells with siRNA or antagonist. Results are presented as means ± SE. g GLP-1 concentration and h OGTT in wild-type (left, n = 10 animals per group), Gpr40-deficient (middle, n = 8 animals per group), and Gpr120-deficient (right, n = 9, 10, and 9 animals per group) mice were analyzed 2 h after FA administration. **P < 0.01 vs. Control (Tukey–Kramer test). #P < 0.05 vs. LA (Tukey–Kramer test). (−) represents the mice without FA administrations. Results are presented as means ± SE. Source data are provided as a Source Data file 6
Fig. 6 HYA contributes to host metabolic condition via GPR40 and GPR120. Mobilization of [Ca2+]i induced by LA-derived gut microbial metabolites was monitored in Flp in a hGPR40 or b hGPR120 T-REx HEK293 cells. Data are presented as Ca2+ intensity. Cells were cultured for 24 h and then treated with or without 10 μg/mL doxycycline (n = 8 independent cultures with doxycycline from three biological replicates; n = 6 independent cultures without doxycycline from two biological replicates). Closed symbols represent values from cells treated with doxycycline, and open symbols denote untreated groups. c–f The inhibitory effects of c Gpr40 and Gpr120 siRNA, d MEK inhibitor (U0126), e PLC inhibitor (U73122), and f CaMKII inhibitor (KN-62) on GLP-1 secretion following LA, HYA, or HYB treatment (n = 4 independent cultures from two biological replicates). **P < 0.01 vs. None (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. LA (Tukey–Kramer test). $$P < 0.01 vs. HYA (Tukey–Kramer test). (−) represents untreated cells with siRNA or antagonist. Results are presented as means ± SE. g GLP-1 concentration and h OGTT in wild-type (left, n = 10 animals per group), Gpr40-deficient (middle, n = 8 animals per group), and Gpr120-deficient (right, n = 9, 10, and 9 animals per group) mice were analyzed 2 h after FA administration. **P < 0.01 vs. Control (Tukey–Kramer test). #P < 0.05 vs. LA (Tukey–Kramer test). (−) represents the mice without FA administrations. Results are presented as means ± SE. Source data are provided as a Source Data file 6CC BY · PubMed Central
Fig. 7 HYA-producing Lactobacillus contributes to host metabolic improvement. Changes in a body weight (n = 10, 10, and 8 per group) and b tissue weight (n = 10 per group) at 16 weeks of age were measured in GF and gnotobiotic mice suffering from HFD-induced obesity. Scale bar; 1 cm. epi, epididymal; peri, perirenal; sub, subcutaneous. c Blood glucose (n = 8, 9, and 9 per group), d total plasma cholesterol (n = 8, 7, and 7 per group), e triglyceride (n = 9, 9, and 10 per group), f GLP-1 (n = 8 per group), and g insulin (n = 7 per group) levels were measured at the end of the experimental period. h mRNA expression of Tnfα in the WAT of HFD-induced obesity (n = 8 per group). i Fecal triglyceride levels were measured at 16 weeks of age (n = 10 per group). j After colonization of lactic acid bacteria for 1 week, OGTT was assessed (n = 7 per group). **P < 0.01; *P < 0.05 vs. GF mice (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA ( + ) (Tukey–Kramer test). k Cecal HYA was quantified in GF and gnotobiotic mice at 16 weeks of age (n = 9, 10, 10, and 7 per group). Results are presented as means ± SE. Source data are provided as a Source Data file 7
Fig. 7 HYA-producing Lactobacillus contributes to host metabolic improvement. Changes in a body weight (n = 10, 10, and 8 per group) and b tissue weight (n = 10 per group) at 16 weeks of age were measured in GF and gnotobiotic mice suffering from HFD-induced obesity. Scale bar; 1 cm. epi, epididymal; peri, perirenal; sub, subcutaneous. c Blood glucose (n = 8, 9, and 9 per group), d total plasma cholesterol (n = 8, 7, and 7 per group), e triglyceride (n = 9, 9, and 10 per group), f GLP-1 (n = 8 per group), and g insulin (n = 7 per group) levels were measured at the end of the experimental period. h mRNA expression of Tnfα in the WAT of HFD-induced obesity (n = 8 per group). i Fecal triglyceride levels were measured at 16 weeks of age (n = 10 per group). j After colonization of lactic acid bacteria for 1 week, OGTT was assessed (n = 7 per group). **P < 0.01; *P < 0.05 vs. GF mice (Tukey–Kramer test). ##P < 0.01; #P < 0.05 vs. HYA ( + ) (Tukey–Kramer test). k Cecal HYA was quantified in GF and gnotobiotic mice at 16 weeks of age (n = 9, 10, 10, and 7 per group). Results are presented as means ± SE. Source data are provided as a Source Data file 7CC BY · PubMed Central
Fig. 8 Schematic representation. The mechanism by which gut microbial metabolism of dietary PUFAs confers host resistance to obesity
Fig. 8 Schematic representation. The mechanism by which gut microbial metabolism of dietary PUFAs confers host resistance to obesityCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Sorted by citations

See all 392

Related

Metadata

Authors
Miyamoto, J., Igarashi, M., Watanabe, K., Karaki, S.-I., Mukouyama, H., Kishino, S., Li, X., Ichimura, A., Irie, J., Sugimoto, Y., Mizutani, T., Sugawara, T., Miki, T., Ogawa, J., Drucker, D. J., Arita, M., Itoh, H., & Kimura, I.
Affiliations
  • Japan Agency for Medical Research and Development (JP)
  • Tokyo University of Agriculture and Technology (JP)
  • Shizuoka University (JP)
  • Kyoto University (JP)
  • Keio University (JP)
  • Chiba University (JP)
  • Mount Sinai Hospital (CA)
Corresponding author
Kimura, Ikuo
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2019-09-05
Volume
10
Issue
1
Pages
4007-4007
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-019-11978-0
PMC
PMC6728375
OpenAlex
W2971602650
Cited by
392
References
40
Citations by year
2026: 46 · 2025: 60 · 2024: 65 · 2023: 62 · 2022: 64 · 2021: 51 · 2020: 40 · 2019: 1
FWCI
12.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • MEXT | Japan Society for the Promotion of Science (JP15H05344, JP16H01355)
  • Japan Agency for Medical Research and Development (JP18gm1010007)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
gut microbiota, obesity, omega-6 fatty acids, high-fat diet, linoleic acid metabolites, Lactobacillus, free fatty acid receptors, adipose tissue inflammation, arachidonic acid, energy metabolism, metabolic disorders
MeSH terms
Gastrointestinal Microbiome, Adipose Tissue, Animals, Cell Line, Dietary Fats, Unsaturated, Energy Metabolism, Fatty Acids, Unsaturated, Humans, Inflammation, Lactobacillus, Metabolic Diseases, Mice, Inbred C57BL, Obesity, Oleic Acids, Dietary Supplements, Linoleic Acid, Models, Animal, Fatty Acids, Omega-6, Mice, Diet, High-Fat, Diet, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review